Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Caratfill is an injectable dermal filler developed by CelestaPro for aesthetic soft-tissue augmentation and wrinkle correction. It is composed of cross-linked hyaluronic acid at a concentration of 24 mg/mL, combined with 0.3% lidocaine to minimize pain during administration. The product utilizes NSE™ (Naturally Safe Effective) technology, which is designed to maintain the natural long-chain structure of hyaluronic acid, thereby ensuring high elasticity and cohesiveness while reducing chemical deformation and potential side effects. Caratfill is administered via injection into the dermal or subcutaneous layers to restore facial volume, smooth deep wrinkles and folds, and enhance facial contours in areas such as the cheeks, forehead, nose, and chin. It has received certifications from the Korean Food and Drug Administration (KFDA) and follows Good Manufacturing Practice (GMP) standards.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Caratfill.